The overexpression of GUSB has been reported to cause primary resistance to immunotherapy in hepatocellular carcinoma, suggesting a novel strategy for enhancing the efficacy of anti‐PD‐1 therapy.20 The gene discussed is GUSB; the disease is hepatocellular carcinoma.